OnCo
key papersKey paper

DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer

Given as the first chemotherapy-type treatment after hormone therapy stopped working, trastuzumab deruxtecan delayed progression by about five months compared with standard chemotherapy, including in tumours with barely detectable HER2.

Open-label phase 3 trial of 866 patients with hormone-receptor-positive metastatic breast cancer that was HER2-low (IHC 1+ or 2+/ISH-negative) or HER2-ultralow (IHC 0 with faint membrane staining), who had progressed on endocrine therapy but had not received chemotherapy for metastatic disease. Patients were randomised to trastuzumab deruxtecan or physician's choice chemotherapy (capecitabine, paclitaxel or nab-paclitaxel). Primary endpoint was PFS in the HER2-low group.

Median PFS was 13.2 vs 8.1 months (HR 0.62) in HER2-low patients, with a similar effect in the ultralow subgroup. It moved T-DXd one line earlier and pushed the HER2 threshold down to almost any detectable staining.

Randomised controlled trialChanged practice866 participants
Authors
Bardia A, Hu X, Dent R, et al.
What it found
  • HER2-low: median PFS 13.2 vs 8.1 months, HR 0.62 (95% CI 0.51-0.74).
  • HER2-ultralow (about 150 patients): median PFS 13.2 vs 8.3 months, HR 0.78, consistent with the HER2-low result.
  • Objective response rate roughly 57% vs 31% in the HER2-low group.
  • Overall survival was immature at the primary analysis and not significantly different.
  • Interstitial lung disease in about 11% of T-DXd patients, with a small number of fatal cases.
What it means

Patients with hormone-receptor-positive metastatic breast cancer that has stopped responding to endocrine therapy can be offered trastuzumab deruxtecan as their first chemotherapy-type treatment if the tumour shows any HER2 staining, rather than waiting until after conventional chemotherapy. Whether to use it before or after chemotherapy is now a choice, since overall survival was not shown to differ and the drug carries a risk of lung inflammation.

Be careful
  • No overall survival benefit was demonstrated at the primary analysis, so the case for using it earlier rests on PFS and response.
  • HER2-ultralow scoring is even less reproducible than HER2-low, and the ultralow subgroup was small and exploratory.
  • Comparator chemotherapy was single-agent and the trial was open-label.
  • Cost and pneumonitis risk are much higher than for capecitabine, which many patients tolerate well for a long time.

Connected

22top

Pages like this

not linked directly; found by shared links